{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-003784","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.212904+00:00","generated_at":"2026-06-06T05:12:31.743871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Baxter Q4 sales $3.89B (+4%); full-year adj. EPS $2.60","bullets":["Q4 sales from continuing ops $3.89B (+4% reported, +3% constant currency); GAAP EPS $0.14, adjusted EPS $0.88.","Full-year 2023 sales $14.81B (+2% reported, +3% constant currency); GAAP diluted loss ($0.15), adjusted EPS $2.60.","Company progressed on new operating model, sale of BioPharma Solutions, and planned Kidney Care separation.","CEO cited building momentum and improving macroeconomic/supply chain environment in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-003784","json":"https://secwatch.observer/filing/0001628280-24-003784.json","markdown":"https://secwatch.observer/filing/0001628280-24-003784.md","text":"https://secwatch.observer/filing/0001628280-24-003784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828024003784/0001628280-24-003784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828024003784/bax-20240208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:12:31.743871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ebf5f316f4a29d5ddc3ddf868d62972aa82db71","claim":"BAXTER INTERNATIONAL INC reported the full year ended Dec. 31, 2023 results: revenue $14.81 billion, EPS ($0.15). Guidance initiated.","evidence_excerpt":"Full-year sales from continuing operations of $14.81 billion increased 2% on a reported basis and 3% on a constant currency basis • Full-year U.S. GAAP diluted EPS (loss) from continuing operations of ($0.15) and adjusted diluted EPS from continuing operations of $2.60","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000162828024003784/0001628280-24-003784-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended Dec. 31, 2023"},{"label":"Revenue","value":"$14.81 billion"},{"label":"EPS","value":"($0.15)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6ff425ef6a50fbe70dc3f858a29b2f9140e25e6d","claim":"BAXTER INTERNATIONAL INC reported the fourth quarter ended Dec. 31, 2023 results: revenue $3.89 billion, EPS $0.14. Guidance initiated.","evidence_excerpt":"Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis 1 • Fourth-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of $0.14 and adjusted diluted EPS from continuing operations of $0.88","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/10456/000162828024003784/0001628280-24-003784-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended Dec. 31, 2023"},{"label":"Revenue","value":"$3.89 billion"},{"label":"EPS","value":"$0.14"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}